91 related articles for article (PubMed ID: 22963492)
1. Method comparison for CA 15-3, CA 19-9, and CA 125 determination using the new LOCI technique of Dimension Vista 1500 and Immulite 2000 XPI.
Zur B; Holdenrieder S; Albers E; Walgenbach-Brünagel G; Stoffel-Wagner B
J Immunoassay Immunochem; 2012; 33(4):435-45. PubMed ID: 22963492
[TBL] [Abstract][Full Text] [Related]
2. Method comparison for determination of the tumor markers AFP, CEA, PSA and free PSA between Immulite 2000 XPI and Dimension Vista 1500.
Zur B; Holdenrieder S; Walgenbach-Brünagel G; Albers E; Stoffel-Wagner B
Clin Lab; 2012; 58(1-2):97-105. PubMed ID: 22372351
[TBL] [Abstract][Full Text] [Related]
3. A multicentre evaluation of the CA 15-3 assay, CA 19-9 assay and CA 125 II assay on the Bayer Immuno 1 System.
Römer M; Haeckel R; Brux B; Sinha P; Raiko I; Krieg M; Stark M; Seidel D; Hübner U; Schmitz G
Eur J Clin Chem Clin Biochem; 1997 Aug; 35(8):637-44. PubMed ID: 9298356
[TBL] [Abstract][Full Text] [Related]
4. Serum concentrations of CA 125, CA 15-3, CA 19-9 and CEA in normal pregnancy: a longitudinal study.
Ercan Ş; Kaymaz Ö; Yücel N; Orçun A
Arch Gynecol Obstet; 2012 Mar; 285(3):579-84. PubMed ID: 21792548
[TBL] [Abstract][Full Text] [Related]
5. BR-MA, OM-MA, GI-MA and CEA: clinical evaluation using the IMMULITE analyzer.
van Dalen A
Tumour Biol; 1999; 20(3):117-29. PubMed ID: 10213919
[TBL] [Abstract][Full Text] [Related]
6. Effect of Chinese medicines Chan Su, Asian ginseng, Siberian ginseng, and American ginseng on a new digoxin immunoassay based on luminescent oxygen channeling technology.
Dasgupta A; Syklawer E; Johnson M; Hwang SA; Boyd SA; Actor JK
Ther Drug Monit; 2011 Oct; 33(5):644-8. PubMed ID: 21860344
[TBL] [Abstract][Full Text] [Related]
7. [Cryptates applied in tumor marker assays (CEA, AFP, CA 15.3, CA19.9): evaluation of Kryptor (Cis-Bio) analyser].
Gherardi C; Roumier AS; Dubucquoi S; Dessaint JP
Ann Biol Clin (Paris); 1998; 56(1):92-5. PubMed ID: 9754229
[No Abstract] [Full Text] [Related]
8. Significance of serum tumor markers carcinoembryonic antigen, CA 19-9, CA 125, and CA 15-3 in pre-orthotopic liver transplantation evaluation.
Pissaia A; Bernard D; Scatton O; Soubrane O; Conti F; Calmus Y
Transplant Proc; 2009 Mar; 41(2):682-4. PubMed ID: 19328956
[TBL] [Abstract][Full Text] [Related]
9. Multicenter evaluation of the Elecsys CA 125 II assay.
Hubl W; Chan DW; Van Ingen HE; Miyachi H; Molina R; Filella X; Pitzel L; Ruibal A; Rymer JC; Bagnard G; Domke I
Anticancer Res; 1999; 19(4A):2727-33. PubMed ID: 10470230
[TBL] [Abstract][Full Text] [Related]
10. New markers for breast carcinoma-associated antigen in comparison with CA 15-3.
van Dalen A
Anticancer Res; 1996; 16(4B):2339-43. PubMed ID: 8694566
[TBL] [Abstract][Full Text] [Related]
11. Impact of serum tumor marker determination on the management of women with borderline ovarian tumors: multivariate analysis of a French multicentre study.
Poncelet C; Fauvet R; Yazbeck C; Coutant C; Darai E
Eur J Surg Oncol; 2010 Nov; 36(11):1066-72. PubMed ID: 20817462
[TBL] [Abstract][Full Text] [Related]
12. Multicentre tumour marker reference range study.
Wilson AP; Van Dalen A; Sibley PE; Kasper LA; Durham AP; el Shami AS
Anticancer Res; 1999; 19(4A):2749-52. PubMed ID: 10470234
[TBL] [Abstract][Full Text] [Related]
13. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
Ayhan A; Guven S; Guven ES; Kucukali T
Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
[TBL] [Abstract][Full Text] [Related]
14. Measurement of tumor markers in chronic hemodialysis patients.
Tzitzikos G; Saridi M; Filippopoulou T; Makri A; Goulioti A; Stavropoulos T; Stamatiou K
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):50-3. PubMed ID: 20061692
[TBL] [Abstract][Full Text] [Related]
15. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
Jiang XT; Tao HQ; Zou SC
Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
[TBL] [Abstract][Full Text] [Related]
16. Performance characteristics of IMMULITE TPS: a comparison with TPS IRMA.
Einarsson R; Lei JD; Ullrich A; Van Dalen A
Anticancer Res; 1999; 19(4A):2743-7. PubMed ID: 10470233
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the DPC IMMULITE random access immunoassay analyser.
Costongs GM; van Oers RJ; Leerkes B; Janson PC
Eur J Clin Chem Clin Biochem; 1995 Nov; 33(11):887-92. PubMed ID: 8620070
[TBL] [Abstract][Full Text] [Related]
18. Performance characteristics of seven automated CA 125 assays.
Mongia SK; Rawlins ML; Owen WE; Roberts WL
Am J Clin Pathol; 2006 Jun; 125(6):921-7. PubMed ID: 16690492
[TBL] [Abstract][Full Text] [Related]
19. Microchip fluorescence-enhanced immunoaasay for simultaneous quantification of multiple tumor markers.
Shi M; Zhao S; Huang Y; Liu YM; Ye F
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Sep; 879(26):2840-4. PubMed ID: 21873123
[TBL] [Abstract][Full Text] [Related]
20. Multicenter evaluation of a new immunoassay for intact PTH measurement on the Elecsys System 2010 and 1010.
Hermsen D; Franzson L; Hoffmann JP; Isaksson A; Kaufman JM; Leary E; Müller C; Nakatsuka K; Nishizawa Y; Reinauer H; Riesen W; Roth HJ; Steinmüller T; Troch T; Bergmann P
Clin Lab; 2002; 48(3-4):131-41. PubMed ID: 11934215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
